JPH0574359B2 - - Google Patents
Info
- Publication number
- JPH0574359B2 JPH0574359B2 JP8590785A JP8590785A JPH0574359B2 JP H0574359 B2 JPH0574359 B2 JP H0574359B2 JP 8590785 A JP8590785 A JP 8590785A JP 8590785 A JP8590785 A JP 8590785A JP H0574359 B2 JPH0574359 B2 JP H0574359B2
- Authority
- JP
- Japan
- Prior art keywords
- acetylhexosamine
- type
- oxidase
- mutarotase
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- OVRNDRQMDRJTHS-BKJPEWSUSA-N N-acetyl-D-hexosamine Chemical compound CC(=O)NC1C(O)O[C@H](CO)C(O)C1O OVRNDRQMDRJTHS-BKJPEWSUSA-N 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 21
- 102000020006 aldose 1-epimerase Human genes 0.000 claims description 17
- 108091022872 aldose 1-epimerase Proteins 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 108010081916 N-acetylhexosamine oxidase Proteins 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 230000001737 promoting effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 7
- OVRNDRQMDRJTHS-PVFLNQBWSA-N N-acetyl-alpha-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-PVFLNQBWSA-N 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 5
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229950006780 n-acetylglucosamine Drugs 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 4
- 102000004316 Oxidoreductases Human genes 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 229940051921 muramidase Drugs 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
- 108010024957 Ascorbate Oxidase Proteins 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- OVRNDRQMDRJTHS-OZRXBMAMSA-N N-acetyl-beta-D-mannosamine Chemical compound CC(=O)N[C@@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-OZRXBMAMSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 1
- UCSRLIHIVSZSGK-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonic acid;sodium Chemical compound [Na].OS(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 UCSRLIHIVSZSGK-UHFFFAOYSA-N 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- -1 N-acetylhexosamide Chemical class 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
(産業上の利用分野)
本発明は、試料、特に水性液中のN−アセチル
ヘキソサミンの酵素的測定用試薬に関するもので
ある。
体液中のN−アセチルヘキソサミンの酵素的測
定は、多くの糖関係化合物、例えばN−アセチル
ヘキソサミド、シアル酸、ムコ多糖類であるヒア
ルロン酸、コンドロチン硫酸、デルマタン硫酸、
ヘパリン、ヘパラン硫酸、ケタラン硫酸及び酵素
活性、例えばN−アセチルヘキサソミニダーゼ、
ムラミダーゼ、シアリダーゼ等の定量に利用され
る。
そしてこれらの臨床的意義として、N−アセチ
ルヘキソサミニダーゼ活性の測定は腎疾患、特に
近位尿細管障害、腎移植拒絶反応等の早期発見
に、ムラミダーゼ活性の測定は、急性単球白血
病、非典型的結核症等の診断に、シアル酸の定量
は、炎症的疾患等の診断にシアリダーゼ活性は、
細菌感染症等の診断に、ムコ多糖の測定はムコ多
糖症の診断等に有効な情報を与える。
(従来の技術)
従来、N−アセチルヘキソサミンを定量する適
当な方法はなく、N−アセチルヘキソサミニダー
ゼ等の酵素活性などは他の反応生成物を測定する
ことにより求められていた。例えば、N−アセチ
ルヘキソサミニダーゼ活性やβ−グロクロニダー
ゼ活性等は、p−ニトロフエニル等の発色団を結
合したクロモジエニツクな基質を用いて、酵素反
応により生じた発色団を比色定量することによ
り、その酵素活性を求めていた。この方法は、酵
素の至適PHと発色団PHが異なるために操作が繁雑
である。また、ムラミダーゼ活性は、生菌体を基
質としてその溶菌速度により活性を求めるため定
量的でなく、バラツキが大である。シアル酸は、
化学的方法、チオバルビツール酸法では特異性が
低く操作が繁雑である。
また、反応生成物であるピルビン酸を測定する
ことにより、シアル酸量を求める酵素法は内因性
ピルビン酸により正確性の点で問題がある。シア
リダーゼは、シアリルラクトースを基質として遊
離したシアル酸を測定するaminoff法が知られて
いるが感度、正確性の点で問題である。ムコ多糖
類には定量法として適当なものがない等の欠点が
ある。本発明者等は、これらの事情を考慮して、
正確で簡便、迅速な糖関連化合物および酵素活性
の定量法を見出し先に特許出願した(特願昭59−
42652号)。つまりN−アセチルヘキソミンに水お
よび酸素の存在下、反応させて過酸化水素を生成
するN−アセチルヘキソサミンオキシダーゼを試
料に作用させ、生成する過酸化水素または消費す
る酸素を測定することを特徴とするN−アセチル
ヘキソサミンの酵素法による定量法である。
この方法により従来法に比べ正確性、簡便性、
迅速性の点は、解決したが反応性の点でまだ不十
分であることがわかつた。
(発明の解決しようとする問題点)
本発明の目的は、N−アセチルヘキサソミンの
酵素的定量法の反応性を向上させることにより、
更に実用性を増す点にある。
(問題点を解決しようとするための手段)
本発明者らは上記目的を達成するために種々鋭
意検討したところN−アセチルヘキソサミンのア
ノマーの変換(α型→β型)を促進させる作用が
あるムタロターゼをN−アセチルヘキソサミンオ
キシダーゼの存在下、共役酵素として用いること
により、N−アセチルヘキソサミンオキシダーゼ
の反応性を促進し従来にもまして正確で、簡便な
操作にて迅速にN−アセチルヘキソサミンを定量
することを見出し本発明に到達した。
すなわち本発明はN−アセチルヘキソサミンオ
キシダーゼおよびN−アセチルヘキソサミンのア
ノマーの変換(α型→β型)を促進させる作用が
あるムタロターゼを含有することを特徴とするN
−アセチルヘキソサミン測定用試薬である。
本発明において測定するN−アセチルヘキソサ
ミンとしては、N−アセチルグルコサミン、N−
アセチルガラクトサミン、N−アセチルムラミン
酸などがある。N−アセチルヘキソサミンは、糖
関連化合物により、化学的または酵素的な方法で
導かれたN−アセチルヘキソサミンであつてもよ
い。例えばN−アセチルヘキソサミニドに、N−
アセチルヘキソサミニダンゼを作用させて生成し
たN−アセチルヘキソサミンがある。またN−ア
セチルヘキソサミンおよびN−アセチルムラミン
酸とのβ−1,4結合体にムラミダーゼを作用さ
せて生成したN−アセチルグルコサミン及びN−
アセチルヘキソサミン酸がある。さらに結合型シ
アル酸にノイラミニダーゼを作用させてN−アセ
チルノイラミン酸を生成させ、N−アセチルマン
ノサミンとピルビン酸を得る。次いでN−アセチ
ルマンノサミンにアシルグルコサミン−2−エピ
メランゼを作用させたN−アセチルグルコサミン
がある。
N−アセチルヘキソサミンには、例えばN−ア
セチルグルコサミンの場合で説明すると下図のよ
うにβ型、α型の存在が知られている。
(Industrial Application Field) The present invention relates to a reagent for enzymatically measuring N-acetylhexosamine in a sample, particularly an aqueous liquid. Enzymatic measurement of N-acetylhexosamine in body fluids can be performed using a number of sugar-related compounds, such as N-acetylhexosamide, sialic acid, the mucopolysaccharide hyaluronic acid, chondrotin sulfate, dermatan sulfate,
Heparin, heparan sulfate, ketalan sulfate and enzyme activities such as N-acetyl hexasominidase,
Used for quantifying muramidase, sialidase, etc. The clinical significance of these activities is that measurement of N-acetylhexosaminidase activity is useful for early detection of renal diseases, especially proximal tubular disorders, renal transplant rejection, etc., and measurement of muramidase activity is useful for the early detection of renal diseases, especially proximal tubular disorders, renal transplant rejection, etc. Quantification of sialic acid is used to diagnose atypical tuberculosis, etc. Sialidase activity is used to diagnose inflammatory diseases, etc.
Measurement of mucopolysaccharide provides information effective in diagnosing bacterial infections and the like, as well as in diagnosing mucopolysaccharidoses. (Prior Art) Conventionally, there has been no suitable method for quantifying N-acetylhexosamine, and enzyme activities such as N-acetylhexosaminidase have been determined by measuring other reaction products. For example, N-acetylhexosaminidase activity, β-glocuronidase activity, etc. can be determined by colorimetrically quantifying the chromophore produced by the enzymatic reaction using a chromodiic substrate bound to a chromophore such as p-nitrophenyl. The enzyme activity was determined by This method is complicated because the optimum pH of the enzyme and the pH of the chromophore are different. In addition, muramidase activity is not quantitative because it is determined by the rate of lysis using live bacterial cells as a substrate, and there is considerable variation. Sialic acid is
Chemical methods and thiobarbituric acid methods have low specificity and are complicated to operate. Furthermore, the enzymatic method for determining the amount of sialic acid by measuring the reaction product pyruvate has a problem in accuracy due to endogenous pyruvate. Regarding sialidase, the aminoff method is known, which measures sialic acid released using sialyllactose as a substrate, but it has problems in terms of sensitivity and accuracy. Mucopolysaccharides have drawbacks such as the lack of suitable quantitative methods. Taking these circumstances into consideration, the inventors have
We discovered an accurate, simple, and quick method for quantifying sugar-related compounds and enzyme activities and applied for a patent (patent application filed in 1983).
No. 42652). In other words, N-acetylhexosamine oxidase, which reacts with N-acetylhexamine in the presence of water and oxygen to produce hydrogen peroxide, is applied to the sample, and the hydrogen peroxide produced or the oxygen consumed is measured. This is a method for quantifying N-acetylhexosamine using an enzymatic method. This method is more accurate, simple, and
Although the problem of speed was solved, it was found that the problem of reactivity was still insufficient. (Problems to be Solved by the Invention) The purpose of the present invention is to improve the reactivity of an enzymatic determination method for N-acetylhexasomine,
This also increases practicality. (Means for Solving the Problems) In order to achieve the above-mentioned object, the present inventors conducted various studies and found that the effect of promoting the conversion of the anomer of N-acetylhexosamine (from α type to β type) By using mutarotase as a conjugate enzyme in the presence of N-acetylhexosamine oxidase, the reactivity of N-acetylhexosamine oxidase is promoted and N-acetylhexosamine is rapidly quantified with more accuracy and simple operation than ever before. This discovery led to the present invention. That is, the present invention is characterized in that it contains N-acetylhexosamine oxidase and mutarotase that has the effect of promoting the conversion of the anomer of N-acetylhexosamine (from α type to β type).
-A reagent for measuring acetylhexosamine. N-acetylhexosamine to be measured in the present invention includes N-acetylglucosamine, N-
Examples include acetylgalactosamine and N-acetylmuramic acid. N-acetylhexosamine may be derived from sugar-related compounds by chemical or enzymatic methods. For example, N-acetylhexosaminide, N-
There is N-acetylhexosamine produced by the action of acetylhexosaminidanse. In addition, N-acetylglucosamine and N-acetylglucosamine and N-
There is acetylhexosaminic acid. Furthermore, neuraminidase is allowed to act on the bound sialic acid to generate N-acetylneuraminic acid, thereby obtaining N-acetylmannosamine and pyruvic acid. Next, there is N-acetylglucosamine, which is obtained by treating N-acetylmannosamine with acylglucosamine-2-epimeranase. For example, in the case of N-acetylglucosamine, it is known that N-acetylhexosamine exists in β-type and α-type as shown in the figure below.
【式】N−アセチル−β−D−グル コサミン[Formula] N-acetyl-β-D-glue Cosamine
【式】N−アセチル−α−D−グル
コサミン
本発明に用いるムタロターゼとは上記N−アセ
チルヘキソサミンのアノマーの変換(α型→β
型)を促進させる作用がある酵素であつて、D−
グルコースの立体配置をもつペンタオースとヘキ
サオースが基質となる既知のムタロターゼ
(Methods Enzymol 41、471(1975))には、確
認できない作用である。一方、既知のN−アセチ
ルヘキソサミンオキシダーゼには、アノマーに体
する基質特異性が知られており、特にβ型に特異
性が高い。
本発明ではN−アセチルヘキソサミンのアノマ
ーの変換(α型→β型)を促進させる作用がある
ムタロターゼが存在することによつて水溶液中に
共存するα型、β型のN−アセチルヘキソサミン
がβ型のみに変換されるためにβ型に体する基質
特異性の高いN−アセチルヘキソサミンオキシダ
ーゼが作用しやすくなり反応性が向上する。
本発明に用いるムタロターゼは、N−アセチル
ヘキソサミンのアノマー変換(α型→β型)を促
進させる作用がある酵素であれば、いかなる起源
のものでもよいが、例えばブタの腎臓から得られ
ているムタロターゼがある。ムタロターゼの濃度
は17μ/ml以上であることが好ましい。
本発明に用いるN−アセチルヘキソサミンオキ
シダーゼはいかなる起源のものでもよいが、例え
ばシユードモナス属に属する微生物が産出するN
−アセチルヘキソサミンオキシダーゼがある。N
−アセチルヘキソサミンオキシダーゼの精製と性
質については日本農芸化学会、昭和58年度大会に
おいて発表されている。N−アセチルヘキソサミ
ンオキシダーゼ濃度は0.1単位/ml以上であるこ
とが好ましい。
本発明の試薬にはN−アセチルヘキソサミンオ
キシダーゼおよびムタロターゼのほかに、必要に
よりペルオキシダーゼあるいはカタラーゼと発色
剤、例えばフエノール誘導体またはアニリン誘導
体、さらにはアスコルビン酸オキシダーゼを含ん
でいてもよい。また本発明の測定試薬はPHが4.0
〜10.0であることが好ましい。
試料に該試薬を作用させる条件としては、特に
限定はないがPH4.0〜10.0を保つ適当な緩衝液を
用い、反応温度20〜50℃が適当である。緩衝液の
種類は特に制限されない。使用PHに最適な緩衝液
を選択すればよい。例えば中性域では、リン酸緩
衝液、グツト緩衝液、酸性域では酢酸緩衝液、ア
ルカリ域では、トリス塩酸緩衝液などがある。緩
衝液の濃度は特に限定されないが通常0.01m〜1
m程度である。また必要に応じて界面活性剤等を
添加してもよい。
本発明の試薬を用いてN−アセチルヘキサソミ
ンを定量する方法としては、試料を該試薬と反応
させて生成する過酸化水素を、例えばペルオキシ
ダーゼあるいはカタラーゼおよび発色剤と共役さ
せて吸光度測定するか、または直接過酸化水素電
極により電気化学的に測定する。
過酸化水素の定量を妨害する試料中のアスコル
ビン酸は、アスコルビン酸オキシダーゼを作用さ
せることによつて除去することができる。この場
合アスコルビン酸オキシダーゼは、他の酵素反応
に先立つて作用させてもまた他の酵素と同時に作
用させて除去してもよい。アスコルビン酸オキシ
ダーゼは、微生物由来のものまたは植物由来のも
のでもよいが、特にカボチヤ、キユウリ等の植物
由来のものが好ましい。
(作用)
N−アセチルヘキソサミンオキシダーゼを用い
るN−アセチルヘキソサミン測定試薬において、
共役酵素としてN−アセチルヘキソサミンのアノ
マーの変換(α型→β型)を促進させる作用があ
るムタロターゼを共存させることにより、反応性
を良くし試薬中のN−アセチルヘキソサミン及び
化学的、酵素的な方法により交換されて導びかれ
てきたN−アセチルヘキソサミンを正確、簡便、
迅速に定量することが出来る。
(実施例)
以下、本発明を実施例により詳細に説明する。
参考例 1
ブタ腎臓皮質285gを0.3Mリン酸カリ緩衝液
(PH7.6)570mlで均一化し遠心分離(8000γpm×
30分)をし得られたエキス分640mlに同量の蒸留
水、2%硫酸プロタミン19.2mlを加え、遠心分離
(同上)、そして得られた沈澱物を0.01Mリン酸カ
リ緩衝液(PH7.6)427mlで第1洗浄、0.025Mリ
ン酸カリ緩衝液(PH7.6)192mlで第2、第3洗浄
を施した。最終段階として、得られたプロタミン
抽出液150mlに2.565gベントナイトを含んだ
0.001MEDTA溶液28.5mlを添加し、遠心分離
(8000γpm×20分)し、そして得られたベントナ
イトエキス170mlを限外濾過濃縮し、ムタロター
ゼ4.4mlが精製できた。
実施例 1
被検体中のN−アセチルヘキソサミン量を下記
試薬を用い、下記方法により定量した。
1 試薬
N−アセチルヘキソサミンオキシダーゼ 1単位
4−アミノアンチピリン 0.5mg
N−エチル−N−(2−ヒドロキシ−3−スル
ホプロピル)−m−トルイジンナトリウム 2mg
ムタロターゼ(参考例1にて製造) 170μ
0.1Mリン酸緩衝液(PH7.0)全量 10ml
2 測定方法
溶液または既知濃度のN−アセチルヘキソサ
ミン20μをとり、これに上記試薬を用いて吸
光度測定を行なつた。比較のためにムタロター
ゼを添加しない試薬を用い、同様にして吸光度
測定を行つた。その結果を第1図に示す。
(発明の効果)
N−アセチルヘキソサミンのアノマーの変換
(α型→β型)を促進させる作用があるムタロタ
ーゼを含有する本発明では、無添加の場合に比し
て反応性が高い。[Formula] N-acetyl-α-D-glucosamine The mutarotase used in the present invention is the conversion of the anomer of N-acetylhexosamine (α type → β type).
It is an enzyme that has the effect of promoting D-
This effect cannot be confirmed in the known mutarotase (Methods Enzymol 41 , 471 (1975)) whose substrates are pentaose and hexaose, which have the configuration of glucose. On the other hand, known N-acetylhexosamine oxidase is known to have substrate specificity in the form of an anomer, and has particularly high specificity for the β type. In the present invention, due to the presence of mutarotase which has the effect of promoting the conversion of the anomer of N-acetylhexosamine (from α type to β type), the α type and β type N-acetylhexosamine coexisting in the aqueous solution are converted to the β type. Since N-acetylhexosamine oxidase, which is converted into the β form and has high substrate specificity, acts more easily, the reactivity is improved. The mutarotase used in the present invention may be of any origin as long as it has the effect of promoting the anomeric conversion of N-acetylhexosamine (from α type to β type), but for example, mutarotase obtained from pig kidney can be used. There is. The concentration of mutarotase is preferably 17 μ/ml or more. The N-acetylhexosamine oxidase used in the present invention may be of any origin, but for example, N-acetylhexosamine oxidase produced by a microorganism belonging to the genus Pseudomonas can be used.
-There is acetylhexosamine oxidase. N
-The purification and properties of acetylhexosamine oxidase were presented at the 1988 annual meeting of the Japanese Society of Agricultural Chemistry. The N-acetylhexosamine oxidase concentration is preferably 0.1 unit/ml or more. In addition to N-acetylhexosamine oxidase and mutarotase, the reagent of the present invention may optionally contain peroxidase or catalase, a coloring agent such as a phenol derivative or an aniline derivative, and further, ascorbic acid oxidase. Furthermore, the measurement reagent of the present invention has a pH of 4.0.
~10.0 is preferred. The conditions under which the reagent is allowed to act on the sample are not particularly limited, but it is appropriate to use an appropriate buffer that maintains the pH between 4.0 and 10.0, and at a reaction temperature of 20 to 50°C. The type of buffer solution is not particularly limited. Just select the buffer solution that is most suitable for the pH used. For example, in a neutral range, phosphate buffer or Gutt's buffer is used, in an acidic range, an acetate buffer is used, and in an alkaline range, a Tris-HCl buffer is used. The concentration of the buffer solution is not particularly limited, but is usually 0.01m to 1
It is about m. Further, a surfactant or the like may be added as necessary. As a method for quantifying N-acetylhexasomine using the reagent of the present invention, hydrogen peroxide produced by reacting a sample with the reagent is conjugated with, for example, peroxidase or catalase and a coloring agent, and the absorbance is measured; Alternatively, it can be measured directly electrochemically using a hydrogen peroxide electrode. Ascorbic acid in the sample, which interferes with the determination of hydrogen peroxide, can be removed by the action of ascorbate oxidase. In this case, ascorbate oxidase may be removed by acting prior to other enzyme reactions or by acting simultaneously with other enzymes. Ascorbic acid oxidase may be derived from microorganisms or plants, but those derived from plants such as pumpkin and cucumber are particularly preferred. (Action) In a reagent for measuring N-acetylhexosamine using N-acetylhexosamine oxidase,
By coexisting mutarotase, which has the effect of promoting the conversion of the anomer of N-acetylhexosamine (from α type to β type) as a conjugate enzyme, reactivity is improved and N-acetylhexosamine in the reagent and chemical and enzymatic Accurately, easily,
Can be quantified quickly. (Example) Hereinafter, the present invention will be explained in detail with reference to Examples. Reference example 1 285g of pig kidney cortex was homogenized with 570ml of 0.3M potassium phosphate buffer (PH7.6) and centrifuged (8000γpm
30 minutes), add the same amount of distilled water and 19.2 ml of 2% protamine sulfate to the resulting extract (640 ml), centrifuge (same as above), and add the resulting precipitate to 0.01 M potassium phosphate buffer (PH7. 6) The first wash was performed with 427 ml, and the second and third washes were performed with 192 ml of 0.025M potassium phosphate buffer (PH7.6). As a final step, 150 ml of the resulting protamine extract contained 2.565 g of bentonite.
28.5 ml of 0.001 MEDTA solution was added, centrifuged (8000 γ pm x 20 minutes), and 170 ml of the obtained bentonite extract was concentrated by ultrafiltration, yielding 4.4 ml of mutarotase. Example 1 The amount of N-acetylhexosamine in a specimen was determined using the following reagent and the following method. 1 Reagent N-acetylhexosamine oxidase 1 unit 4-aminoantipyrine 0.5mg N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-toluidine sodium 2mg Mutarotase (manufactured in Reference Example 1) 170μ 0.1M phosphorus Acid buffer solution (PH7.0) total volume: 10 ml 2. Measurement method A solution or 20 µ of N-acetylhexosamine with a known concentration was taken, and the absorbance was measured using the above reagent. For comparison, absorbance measurements were performed in the same manner using a reagent to which mutarotase was not added. The results are shown in FIG. (Effects of the Invention) The present invention, which contains mutarotase which has the effect of promoting the conversion of the anomer of N-acetylhexosamine (from α type to β type), has higher reactivity than when no additive is used.
第1図はムタロターゼを含有する本発明試薬と
ムタロターゼ無添加の試薬との反応曲線を示す。
FIG. 1 shows a reaction curve between a reagent of the present invention containing mutarotase and a reagent without mutarotase.
Claims (1)
びN−アセチルヘキソサミンのアノマーの変換
(α型→β型)を促進させる作用があるムタロタ
ーゼを含有することを特徴とするN−アセチルヘ
キソサミン測定用試薬。1. A reagent for measuring N-acetylhexosamine, which contains N-acetylhexosamine oxidase and mutarotase, which has the effect of promoting the conversion of the anomer of N-acetylhexosamine (from α type to β type).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8590785A JPS61242595A (en) | 1985-04-22 | 1985-04-22 | Reagent for determination of n-acetylhexosamine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8590785A JPS61242595A (en) | 1985-04-22 | 1985-04-22 | Reagent for determination of n-acetylhexosamine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61242595A JPS61242595A (en) | 1986-10-28 |
| JPH0574359B2 true JPH0574359B2 (en) | 1993-10-18 |
Family
ID=13871903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8590785A Granted JPS61242595A (en) | 1985-04-22 | 1985-04-22 | Reagent for determination of n-acetylhexosamine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61242595A (en) |
-
1985
- 1985-04-22 JP JP8590785A patent/JPS61242595A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61242595A (en) | 1986-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU797592A3 (en) | Method of determining substrate or enzymic activity in biological material | |
| Rauscher et al. | Optimized conditions for determining activity concentration of alpha-amylase in serum, with 1, 4-alpha-D-4-nitrophenylmaltoheptaoside as substrate. | |
| JPH0426624B2 (en) | ||
| WO1995004831A1 (en) | Method of determining chloride ion | |
| JP4465452B2 (en) | Endotoxin concentration measurement method and endotoxin concentration measurement kit | |
| JPH0574359B2 (en) | ||
| EP0201333B1 (en) | Reagent for measuring amylase activity and measuring method thereof | |
| JPH0373276B2 (en) | ||
| EP0104780B1 (en) | Measurement of alpha-amylase activity | |
| JPS61502515A (en) | Method for determining ciliary static factor in cystic fibrosis | |
| JP2872983B2 (en) | Method for quantifying 1,5-anhydroglucitol and reagent for quantification | |
| JPH064038B2 (en) | L-fucose quantification method | |
| US5091305A (en) | Bile acid sulfate sulfatase, process for its preparation and method for assaying bile acid | |
| US5350678A (en) | Method of differential assay for α-amylase isozymes and a kit for the same | |
| US5055398A (en) | Process for measuring the concentration of a component in body fluid such as urine or blood | |
| JP3901990B2 (en) | Reagent for measuring α-amylase activity and measurement method | |
| Ampon et al. | A spectrophotometric method for the determination of glucose with glucose oxidase [ec 1.11. 1.7] using titanium (iv)-4-(2'-pyridylazo) resorcinol reagent | |
| JP3597909B2 (en) | Method and reagent for quantitative determination of chloride ion | |
| JPH0710237B2 (en) | N-acetylhexosaminidase activity assay method | |
| JPH054080B2 (en) | ||
| JP2000346849A (en) | New disease detection means | |
| JPS5876100A (en) | Use of laccase | |
| JPH0517837B2 (en) | ||
| JPS60157044A (en) | Amylase analyzer | |
| JPS60186300A (en) | Determination of n-acetylhexosamine |